BR0214319A - Uso de um agonista de receptor de canabinóide ou um sal farmaceuticamente aceitável ou um isÈmero ótico do mesmo, e, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, o tratamento de doença do refluxo gastroesofágico, a prevenção do refluxo, o tratamento ou prevenção da regurgitação, doença do pulmão, asma e de laringite crÈnica e para controlar insuficiência de desenvolvimento - Google Patents

Uso de um agonista de receptor de canabinóide ou um sal farmaceuticamente aceitável ou um isÈmero ótico do mesmo, e, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, o tratamento de doença do refluxo gastroesofágico, a prevenção do refluxo, o tratamento ou prevenção da regurgitação, doença do pulmão, asma e de laringite crÈnica e para controlar insuficiência de desenvolvimento

Info

Publication number
BR0214319A
BR0214319A BR0214319-4A BR0214319A BR0214319A BR 0214319 A BR0214319 A BR 0214319A BR 0214319 A BR0214319 A BR 0214319A BR 0214319 A BR0214319 A BR 0214319A
Authority
BR
Brazil
Prior art keywords
treatment
prevention
regurgitation
asthma
inhibition
Prior art date
Application number
BR0214319-4A
Other languages
English (en)
Inventor
Anders Lehmann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0214319A publication Critical patent/BR0214319A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"USO DE UM AGONISTA DE RECEPTOR DE CANABINóIDE OU UM SAL FARMACEUTICAMENTE ACEITáVEL OU UM ISÈMERO óTICO DO MESMO, E, MéTODOS PARA A INIBIçãO DE RELAXAMENTOS TRANSITóRIOS DO ESFìNCTER ESOFáGICO INFERIOR, O TRATAMENTO DE DOENçA DO REFLUXO GASTROESOFáGICO, A PREVENçãO DO REFLUXO, O TRATAMENTO OU PREVENçãO DA REGURGITAçãO, DOENçA DO PULMãO, ASMA E DE LARINGITE CRÈNICA E PARA CONTROLAR INSUFICIêNCIA DE DESENVOLVIMENTO". A presente invenção refere-se ao uso de agonistas de receptor de canabinóides, para a inibição dos relaxamentos transitórios do esfíncter esofágico inferior. Um outro aspecto da invenção é direcionado ao uso de agonistas de receptor de canabinóides, para o tratamento da doença do refluxo gastroesofágico, bem como para o tratamento da regurgitação, tal como regurgitação em crianças, doença de pulmão, laringite crónica e asma.
BR0214319-4A 2001-11-23 2002-11-20 Uso de um agonista de receptor de canabinóide ou um sal farmaceuticamente aceitável ou um isÈmero ótico do mesmo, e, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, o tratamento de doença do refluxo gastroesofágico, a prevenção do refluxo, o tratamento ou prevenção da regurgitação, doença do pulmão, asma e de laringite crÈnica e para controlar insuficiência de desenvolvimento BR0214319A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103936 2001-11-23
PCT/SE2002/002108 WO2003043619A1 (en) 2001-11-23 2002-11-20 New use for the treatment of gastroesophageal reflux disease

Publications (1)

Publication Number Publication Date
BR0214319A true BR0214319A (pt) 2004-11-03

Family

ID=20286096

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214319-4A BR0214319A (pt) 2001-11-23 2002-11-20 Uso de um agonista de receptor de canabinóide ou um sal farmaceuticamente aceitável ou um isÈmero ótico do mesmo, e, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, o tratamento de doença do refluxo gastroesofágico, a prevenção do refluxo, o tratamento ou prevenção da regurgitação, doença do pulmão, asma e de laringite crÈnica e para controlar insuficiência de desenvolvimento

Country Status (20)

Country Link
US (1) US7358245B2 (pt)
EP (1) EP1453497A1 (pt)
JP (1) JP2005511632A (pt)
KR (1) KR20050044582A (pt)
CN (1) CN1610542A (pt)
AR (1) AR037299A1 (pt)
AU (1) AU2002353700A1 (pt)
BR (1) BR0214319A (pt)
CA (1) CA2466916A1 (pt)
HU (1) HUP0402080A3 (pt)
IL (1) IL161748A0 (pt)
IS (1) IS7272A (pt)
MX (1) MXPA04004774A (pt)
NO (1) NO20042613L (pt)
NZ (1) NZ532844A (pt)
PL (1) PL369402A1 (pt)
RU (1) RU2280443C2 (pt)
TW (1) TW200407110A (pt)
WO (1) WO2003043619A1 (pt)
ZA (1) ZA200403785B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039550A2 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
SE0303490D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use V
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
CN101132781A (zh) * 2004-12-09 2008-02-27 茵西斯医疗公司 在室温下稳定的屈大麻酚剂型
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
EP2205240A1 (en) 2007-10-02 2010-07-14 Ariel-University Research And Development Company, Ltd. Endocannabinoids for enhancing growth and development in infants
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
CN103588672A (zh) * 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
CA2340445A1 (en) 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
AU776414B2 (en) 1998-05-29 2004-09-09 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
IL132661A (en) 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
US6645987B2 (en) * 2000-06-15 2003-11-11 Schering Corporation Nor-seco himbacine derivatives useful as thrombin receptor antagonists
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Also Published As

Publication number Publication date
JP2005511632A (ja) 2005-04-28
AU2002353700A1 (en) 2003-06-10
MXPA04004774A (es) 2004-07-30
WO2003043619A8 (en) 2005-03-17
HUP0402080A3 (en) 2008-03-28
EP1453497A1 (en) 2004-09-08
HUP0402080A2 (hu) 2005-02-28
TW200407110A (en) 2004-05-16
CN1610542A (zh) 2005-04-27
KR20050044582A (ko) 2005-05-12
RU2280443C2 (ru) 2006-07-27
RU2004114843A (ru) 2005-05-27
WO2003043619A1 (en) 2003-05-30
IL161748A0 (en) 2005-11-20
NO20042613L (no) 2004-08-13
ZA200403785B (en) 2005-05-19
AR037299A1 (es) 2004-11-03
PL369402A1 (en) 2005-04-18
US20040266861A1 (en) 2004-12-30
US7358245B2 (en) 2008-04-15
CA2466916A1 (en) 2003-05-30
NZ532844A (en) 2005-12-23
IS7272A (is) 2004-05-19

Similar Documents

Publication Publication Date Title
BR0214319A (pt) Uso de um agonista de receptor de canabinóide ou um sal farmaceuticamente aceitável ou um isÈmero ótico do mesmo, e, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, o tratamento de doença do refluxo gastroesofágico, a prevenção do refluxo, o tratamento ou prevenção da regurgitação, doença do pulmão, asma e de laringite crÈnica e para controlar insuficiência de desenvolvimento
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
DE60124524D1 (de) Optisches reduktionssystem mit kontrolle der belichtungspolarisation
BRPI0415119A (pt) derivados de acilhidrazona e uso dos mesmos relacionado na inibição, regulação e/ou modulação da transdução do sinal da quinase
ATE258928T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
CY2014019I2 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
ATE259796T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
DE60124863D1 (de) Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
PT1196408E (pt) Inibidores da replicacao do virus sincicial respiratorio
CL2007003260A1 (es) Compuestos derivados de azabiciclo[2.2.2]octano; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedad pulmonar obstructiva cronica.
NO20035749L (no) Fremgangsmate for kontantlos spillvirksomhet
DE60114044D1 (de) Herstellung beschichteter medizinischer geräte mittels laserablation
BRPI0309513A2 (pt) composição para tratamento de fibras com efeito durável
PT1309324E (pt) Derivados de anticonvulsivos uteis para o tratamento e prevencao do desenvolvimento de diabetes mellitus do tipo ii e da sindroma x
DE60319997D1 (de) Topische emulsionsgel-zubereitung enthaltend diclofenac-natrium
BR0311759A (pt) Usos de um antagonista do receptor 5 do glutamato metabotrópico ou um sal farmaceuticamente aceitável ou um isÈmero óptico do mesmo e métodos de inibição de relaxamentos transientes do esfìncter esofagiano inferior, de tratamento da doença do refluxo gastro-esofagiano, de prevenção do refluxo, de tratamento ou prevenção da regurgitação, de doença pulmonar, da asma, de laringites crÈnicas e de administração da falta de desenvolvimento
NO20032283L (no) Belegg for å hindre erosjon av brönnhullskomponenter
PE20020547A1 (es) Uso de la tolterodina en tratamientos del asma
NO20030585L (no) Bruk av triazintrionsulfoner for a bekjempe koksidiose
BRPI0507916A (pt) moduladores de oxidecahidronaftaleno de hm74
FR2910678B1 (fr) Structure de plan de vol modifiable n'affectant pas ses contraintes operationnelles
AR059789A1 (es) "dominios kunitz quimericos y su uso "
FI20011069A0 (fi) Uusia vetoelimien käyttöjä puurakentamisessa
FR2874855B1 (fr) Instrument d'ecriture
ATE325120T1 (de) Neue verwendung substituierter aminomethylchromane

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6, DA RPI 2108 DE 31/05/2011.